The information you provide to the chat will be collected and recorded to improve your experience and for quality assurance. Please read our privacy policy to see how we are storing and protecting your data.
How can we help you today?
Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
Search Patheon
Recent searches
Clear History
Suggestions
All Results
Recent searches
Clear History
Suggestions
All Results
Search
US | EN
By harnessing solid-state characterization and crystallization development from early stages, pharmaceutical companies can accelerate their product timelines and minimize costly errors. Understanding the solid form landscape is crucial for creating a scalable crystallization process that ensures purity and optimizes bioavailability. This proactive approach in defining solid-state parameters early in development enhances control over drug substance and drug product processes, leading to more effective development.
This article highlights the importance of a global network and integration with drug product formulation development to speed up market readiness. Early investment in synthetic route finding and a better understanding of the solid-state properties and crystallization of the drug candidate can avoid the trial-and-error cycle and streamline the progression to commercialization. By focusing on these advanced methodologies, pharmaceutical companies can refine their production strategies and improve outcomes.
